Peptide and Anticoagulant Drugs Market - By Type (Hormonal, Insulin, Teriparatide, Leuprolide Acetate, Antibiotic, Eptifibatide, Warfarin, ACE Inhibitor, Antifungal, Other Peptide Drugs, Anticoagulants, Enoxaparin Sodium, Heparin Sodium, Others) By Application (Diabetes, Infectious Diseases, Cancer, Osteoporosis, Cardiology, Genecology, Others) By End-Users (Introduction, Hospitals and clinics, Research Centers, Diagnostic Centers) By Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Industry Analysis, Opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 196
Status: Published
Report Code: ARI100735
Some of them occur naturally in blood-eating animals, it helps to keep the bitten area unclotted long enough for the animal to obtain some blood. Anticoagulants are related to and thrombolytic drugs and antiplatelet drugs by manipulating the various pathways of blood coagulation which inhibit platelet aggregation. These drugs are majorly used for deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. Peptides are long chain amino acids. Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of this market. Also, an increase in the rate of Diabetes and Cancer promotes the growth of the market. According, to WHO in 2017 diabetes patients has risen from 108 million in 1980 to 422 million in 2014.. Also predicted that breast cancer rates are highest in non-Hispanic white women, breast cancer death rates are highest in African American women which increase the growth of peptide and anticoagulant drugs market in the forecast period. However, the higher price of NOACs and lack of antidots for NOACs impede the market growth. The growth of peptide and anticoagulant drugs market enhanced by the growing cases of peptide and anticoagulant drugs which create an opportunity for the other pharma companies to introduce novel therapy and promising pipeline drugs. In addition, advances in the treatment rate and recent approval of drugs are some of the impacting factors to accelerate the growth of peptide and anticoagulant drugs market. Nevertheless, huge financial burden and patent expiration are the factors that hinder the growth of this market.
Peptide are the unique class of therapeutics which are composed of protein called amino acids joined together by a peptide bond. It is recognized that peptides therapeutics has key role in any biological event and therefore, it has high demand for pharmacological use while anticoagulant is a class of therapeutics that helps in reducing or preventing the blood coagulation. Clotting of blood is physiological action of the body which helps in controlling external bleeding during the time of injuries.
Some of the key players in the global peptide drugs market are Abbott Laboratories (U.S.), Cadila Pharmaceuticals (India), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), and Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India).
Analyst Commentary
The global anticoagulants market is anticipated to show significant market growth during the forecast period, owing to increase in prevalence of ischemic heart disease and venous thromboembolism (VTE) and awareness of novel oral anticoagulants (NOACs). In addition, increasing number of geriatric population and growing incidence of obese population is expected to further increase the demand for anticoagulants throughout the forecast period. On the other side, very high cost of NOACs is expected to negatively affect the growth of the anticoagulants market.
Based on application, Diabetes is dominating the market with the highest revenue share, due to the increasing number of diabetic patients across the globe.
Heart attack segment is a major revenue contributor and is anticipated to show dominance throughout the forecast period, owing to large target population and increase in use of anticoagulants to treat these conditions.
Segmentation
The global peptide and anticoagulant drugs market is segmented on the basis of type, application and end users. The peptide and anticoagulant drugs market by type is hormonal, antibiotic, ACE inhibitor antifungal, other peptide drugs, and anticoagulants on the basis of application, the market is sub-segmented into diabetes, cancer, infectious diseases, cancer, osteoporosis, cardiology, gynaecology, other. On the basis of end users, the market is segmented into hospitals, research centers, and diagnostic centers.
Regional Analysis
It is estimated that North America dominated the global peptide and anticoagulant drugs market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. According, to WHO in it was estimated that diabetes was the cause of 1.6 million deaths. Most of all deaths related to high blood glucose occur before the age of 70 years. WHO also projected that diabetes will be the seventh leading cause of death in 2030 which can be the major leading factor in the growth of peptide and anticoagulant drugs market in this region.
Europe stood second largest in the peptide and anticoagulant drugs market owing to the increasing use of tobacco. According to the Cancer Research UK, 359,960 cases of cancer were found in 2015. Also, 35,620 deaths caused due to lung cancer in this region due to change in lifestyle which can enhance the growth of peptide and anticoagulant drugs market.
Asia-Pacific was projected to be the fastest growing region for the global peptide and anticoagulant drugs market in 2017. The market is expected to witness growth owing to the rising prevalence of cancer, changing lifestyle, and increasing tobacco use within the population. The international diabetes federation estimated 72,946,400 cases of diabetes in India in 2017. Such a high incidence of diabetes cases favors the market growth in this region.
The Middle East and Africa holds the least share in the global peptide and anticoagulant drugs market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.
TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data Component
2.3.1. Secondary Component
2.3.1.1. Preliminary data mining
2.3.2. Primary Component
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Peptide and Anticoagulant Drugs Market
Chapter 5. Global Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
5.1. Global Peptide and Anticoagulant Drugs Market Share, By Type, 2015 - 2027 (USD Million)
5.1.1. Hormonal
5.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. Antibiotics
5.1.2.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. ACE Inhibitor antifungal
5.1.3.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
5.1.4. Others
5.1.4.1. Market Type and Projections,2015 - 2027 (USD Million)
5.1.4.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027(USD Million)
6.1. Global Peptide and Anticoagulant Drugs Market Share, By Application, 2015 - 2027 (USD Million)
6.1.1. Diabetes
6.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
6.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Cancer
6.1.2.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.3. Infectious diseases
6.1.3.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.4. Cancer osteoporosis
6.1.4.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.4.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.5. Cardiology
6.1.5.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.5.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
6.1.6. Gynaecology
6.1.6.1. Market Type and Projections, 2015 - 2027 (USD Million)
6.1.6.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Peptide and Anticoagulant Drugs Market Overview, By End Users, 2015 - 2027(USD Million)
7.1. Global Peptide and Anticoagulant Drugs Market Share, By End Users, 2015 - 2027 (USD Million)
7.1.1. Hospitals
7.1.1.1. Market Type and Projections,2015 - 2027 (USD Million)
7.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
7.1.2. Research centres
7.1.2.1. Market Type and Projections, 2015 - 2027 (USD Million)
7.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
7.1.3. Diagnostic centres
7.1.3.1. Market Type and Projections, 2015 - 2027 (USD Million)
7.1.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 8. Global Peptide and Anticoagulant Drugs Market Overview, By Geography, 2015 - 2027(USD Million)
8.1. Global Peptide and Anticoagulant Drugs Market Share, By Geography, 2015 - 2027(USD Million)
8.1.1. Market Type and projections, by Countries, 2015 - 2027 (USD Million)
8.1.2. Market Share and CAGR Comparison, by Countries, 2020 - 2027 (%)
Chapter 9. North America Peptide and Anticoagulant Drugs Market Overview, By Countries, 2015 - 2027(USD Million)
9.1. North America Peptide and Anticoagulant Drugs Market Overview, 2015 - 2027 (USD Million)
9.1.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.2. North America Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.3. North America Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
9.1.4. North America Peptide and Anticoagulant Drugs Market Overview, By End Users, 2015 - 2027 (USD Million)
9.1.5. North America Peptide and Anticoagulant Drugs Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.5.1. U.S. Peptide and Anticoagulant Drugs Market Overview, 2015 - 2027 (USD Million)
9.1.5.1.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.5.1.2. U.S. Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.5.1.3. U.S. Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
9.1.5.1.4. Other Segment
9.1.5.2. Canada Peptide and Anticoagulant Drugs Market Overview, 2015 - 2027 (USD Million)
9.1.5.2.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.5.2.2. Canada Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.5.2.3. Canada Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
9.1.5.2.4. Other Segment
9.1.5.3. Mexico Peptide and Anticoagulant Drugs Market Overview, 2015 - 2027 (USD Million)
9.1.5.3.1. Market Type and projections, 2015 - 2027 (USD Million)
9.1.5.3.2. Mexico Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.5.3.3. Mexico Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
9.1.5.3.4. Other Segment
Chapter 10. Europe Peptide and Anticoagulant Drugs Market Overview, By Countries, 2015 - 2027(USD Million)
10.1. Europe Peptide and Anticoagulant Drugs Market Overview, 2015 - 2027 (USD Million)
10.1.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.2. Europe Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.3. Europe Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
10.1.4. Europe Peptide and Anticoagulant Drugs Market Overview, By End Users,2015 - 2027 (USD Million)
10.1.5. Europe Skin Care Types Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.5.1. Germany
10.1.5.1.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.5.1.2. Germany Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
10.1.5.1.3. Germany Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027(USD Million)
10.1.5.1.4. Other Segments
10.1.5.2. France
10.1.5.2.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.5.2.2. France Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
10.1.5.2.3. France Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027(USD Million)
10.1.5.2.4. Other Segments
10.1.5.3. UK
10.1.5.3.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.5.3.2. UK Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
10.1.5.3.3. UK Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027(USD Million)
10.1.5.3.4. Other Segments
10.1.5.4. Italy
10.1.5.4.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.5.4.2. Italy Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
10.1.5.4.3. Italy Peptide and Anticoagulant Drugs Market Overview, By Application 2015 - 2027(USD Million)
10.1.5.4.4. Other Segments
10.1.5.5. Spain
10.1.5.5.1. Market Type and projections, 2015 - 2027 (USD Million)
10.1.5.5.2. Spain Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
10.1.5.5.3. Spain Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027(USD Million)
10.1.5.5.4. Other Segments
10.1.5.6. Rest of Europe
10.1.5.6.1. Market Type and projections, 2015 – 2027
10.1.5.6.2. Rest of Europe Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
10.1.5.6.3. Rest of Europe Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027(USD Million)
10.1.5.6.4. Other Segments
Chapter 11. Asia Pacific Peptide and Anticoagulant Drugs Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Asia Pacific Peptide and Anticoagulant Drugs Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.2. Asia Pacific Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.3. Asia Pacific Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
11.1.4. Asia Pacific Peptide and Anticoagulant Drugs Market Overview, By End Users,2015 - 2027 (USD Million)
11.1.5. Asia Pacific Peptide and Anticoagulant Drugs Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.5.1. India
11.1.5.1.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.5.1.2. India Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
11.1.5.1.3. India Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
11.1.5.1.4. Other Segments
11.1.5.2. China
11.1.5.2.1. Market Type and projections, 2015 - 2027(USD Million)
11.1.5.2.2. China Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
11.1.5.2.3. China Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
11.1.5.2.4. Other Segments
11.1.5.3. Japan
11.1.5.3.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.5.3.2. Japan Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
11.1.5.3.3. Japan Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027(USD Million)
11.1.5.3.4. Other Segments
11.1.5.4. South Korea
11.1.5.4.1. Market Type and projections, 2015 - 2027(USD Million)
11.1.5.4.2. South Korea Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
11.1.5.4.3. South Korea Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
11.1.5.4.4. Other Segments
11.1.5.5. Rest of Asia Pacific
11.1.5.5.1. Market Type and projections, 2015 - 2027 (USD Million)
11.1.5.5.2. Rest of Asia Pacific Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027(USD Million)
11.1.5.5.3. Rest of Asia Pacific Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
11.1.5.5.4. Other Segments
Chapter 12. Middle East & Africa Peptide and Anticoagulant Drugs Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. Middle East & Africa Peptide and Anticoagulant Drugs Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.2. Middle East & Africa Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.3. Middle East & Africa Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
12.1.4. Middle East & Africa Peptide and Anticoagulant Drugs Market Overview, By End Users,2015 - 2027 (USD Million)
12.1.5. Middle East & Africa Peptide and Anticoagulant Drugs Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1.5.1. GCC
12.1.5.1.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.5.1.2. GCC Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.5.1.3. GCC Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
12.1.5.1.4. Other Segments
12.1.5.2. South Africa
12.1.5.2.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.5.2.2. South Africa Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.5.2.3. South Africa Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
12.1.5.2.4. Other Segments
12.1.5.3. Rest of Middle East & Africa
12.1.5.3.1. Market Type and projections, 2015 - 2027 (USD Million)
12.1.5.3.2. Rest of Middle East & Africa Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.5.3.3. Rest of Middle East & Africa Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
12.1.5.3.4. Other Segments
Chapter 13. South America Peptide and Anticoagulant Drugs Market Overview, By Countries, 2015 - 2027 (USD Million)
13.1. South America Peptide and Anticoagulant Drugs Market Overview, 2015 - 2027 (USD Million)
13.1.1. Market Type and projections, 2015 - 2027 (USD Million)
13.1.2. South America Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.3. South America Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
13.1.4. South America Peptide and Anticoagulant Drugs Market Overview, By End Users,2015 - 2027 (USD Million)
13.1.5. South America Peptide and Anticoagulant Drugs Market Overview, By Countries, 2015- 2026 (USD Million)
13.1.6. Brazil
13.1.6.1. Market Type and projections, 2015 - 2027 (USD Million)
13.1.6.2. Brazil Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.6.3. Brazil Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
13.1.6.4. Other Segments
13.1.7. Argentina
13.1.7.1. Market Type and projections, 2015 - 2027 (USD Million)
13.1.7.2. Argentina Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.7.3. Argentina Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
13.1.7.4. Other Segments
13.1.8. Rest of South America
13.1.8.1. Market Type and projections, 2015 – 2027
13.1.8.2. Rest of South America Peptide and Anticoagulant Drugs Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.8.3. Rest of South America Peptide and Anticoagulant Drugs Market Overview, By Application, 2015 - 2027 (USD Million)
13.1.8.4. Other Segments
Chapter 14. Competitive Landscape
14.1. Competitive environment, 2021
14.2. Strategic framework
14.2.1. Partnership/agreement
14.2.2. Expansion
14.2.3. Mergers & Acquisitions
14.2.4. New Type development
Chapter 15. Key Vendor Analysis
15.1. Abbott Laboratories
15.1.1. Company overview
15.1.2. Financial performance
15.1.3. Product Benchmarking
15.1.4. Recent initiatives
15.1.5. SWOT analysis
15.2. Sanofi SA
15.2.1. Company overview
15.2.2. Financial performance
15.2.3. Product Benchmarking
15.2.4. Recent initiatives
15.2.5. SWOT analysis
15.3. Cipla liimited
15.3.1. Company overview
15.3.2. Financial performance
15.3.3. Product Benchmarking
15.3.4. Recent initiatives
15.4. Lupin liimited
15.5. Novartis AG Limited
15.6. Alkem laboratories limited
15.7. Sun pharmaceutical limited
15.8. Biocon limited
15.9. Others
Chapter 16. Peptide and Anticoagulant Drugs Market Cost Analysis
16.1. Peptide and Anticoagulant Drugs Market Key Type Analysis
16.1.1. Key Type
16.1.2. Price Trend of Key Type
16.1.3. Key Suppliers of Type
16.1.4. Market Concentration Rate of Type
16.1.5. Labor Cost
Chapter 17. Sourcing Strategy and Downstream Buyers
17.1. Peptide and Anticoagulant Drugs Market Chain Analysis
17.2. Upstream Type Sourcing
17.3. Peptide and Anticoagulant Drugs Market Major Manufacturers in 2021
17.4. Downstream Buyers
Chapter 18. Marketing Strategy Analysis, Distributors/Traders
18.1. Marketing Channel
18.1.1. Direct Marketing
18.1.2. Indirect Marketing
18.1.3. Marketing Channel Development Trend
18.2. Market Positioning
18.2.1. Pricing Strategy
18.2.2. Brand Strategy
18.2.3. Target Client
18.3. Distributors/Traders List
Chapter 19. Market Effect Factors Analysis
19.1. Technology Progress/Risk
19.1.1. Substitutes Threat
19.1.2. Technology Progress in Related Type
19.2. Consumer Needs/Customer Preference Change
19.3. Economic/Political Environmental Change
Chapter 20. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Peptide and Anticoagulant Drugs Market share, By Type, 2020 & 2027 (%)
10. Global Peptide and Anticoagulant Drugs Market share, by Hormonal, By Type, 2015 - 2027 (USD Million)
11. Global Peptide and Anticoagulant Drugs Market share, by Antibiotics, By Type, 2015 - 2027 (USD Million)
12. Global Peptide and Anticoagulant Drugs Market share, by ACE Inhibitor antifungal, By Type, 2015 - 2027 (USD Million)
13. Global Peptide and Anticoagulant Drugs Market share, by Others, By Type, 2015 - 2027 (USD Million)
14. Global Peptide and Anticoagulant Drugs Market share, By Application, 2020 & 2027 (%)
15. Global Peptide and Anticoagulant Drugs Market share, by Diabetes, By Application, 2015 - 2027 (USD Million)
16. Global Peptide and Anticoagulant Drugs Market share, by Cancer, By Application 2015 - 2027 (USD Million)
17. Global Peptide and Anticoagulant Drugs Market share, by Infectious diseases, By Application 2015 - 2027 (USD Million)
18. Global Peptide and Anticoagulant Drugs Market share, by Cancer osteoporosis, By Application 2015 - 2027 (USD Million)
19. Global Peptide and Anticoagulant Drugs Market share, by Cardiology, By Application 2015 - 2027 (USD Million)
20. Global Peptide and Anticoagulant Drugs Market share, by Gynaecology, By Application 2015 - 2027 (USD Million)
21. Global Peptide and Anticoagulant Drugs Market share, By End Users, 2020 & 2027 (%)
22. Global Peptide and Anticoagulant Drugs Market share, by Hospitals, By End Users, 2015 - 2027 (USD Million)
23. Global Peptide and Anticoagulant Drugs Market share, by Research centres, By End Users 2015 - 2027 (USD Million)
24. Global Peptide and Anticoagulant Drugs Market share, by Diagnostic centres, By End Users 2015 - 2027 (USD Million)
25. Global Peptide and Anticoagulant Drugs Market share, by region, 2020 & 2027 (%)
26. Global Peptide and Anticoagulant Drugs Market share, by region, 2015 - 2027(USD Million)
27. North America Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
28. North America Peptide and Anticoagulant Drugs Market share, by Countries, 2020 & 2027 (%)
29. U.S. Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
30. Canada Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
31. Mexico Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
32. Europe Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
33. Europe Peptide and Anticoagulant Drugs Market share, by Countries, 2020 & 2027 (%)
34. Spain Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
35. UK Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
36. Italy Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
37. Germany Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
38. France Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
39. Rest of Europe Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
40. Asia-Pacific Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
41. Asia-Pacific Peptide and Anticoagulant Drugs Market share, by Countries, 2020 & 2027 (%)
42. China Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
43. India Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
44. Australia Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
45. Japan Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
46. Rest of Asia-Pacific Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
47. Middle East & Africa Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
48. Middle East & Africa Peptide and Anticoagulant Drugs Market share, by Countries, 2020 & 2027 (%)
49. GCC Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
50. South Africa Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
51. Rest Of Middle East & Africa Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
52. South America Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
53. Brazil Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
54. Mexico Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
55. Argentina Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
56. Rest Of South America Peptide and Anticoagulant Drugs Market, 2015 - 2027(USD Million)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Peptide and Anticoagulant Drugs Market, 2015-2027 (USD Million)
4. Peptide and Anticoagulant Drugs requirement, by country, 2015-2027, (USD Million)
5. North America Peptide and Anticoagulant Drugs Market, By Type, 2015-2027 (USD Million)
6. North America Peptide and Anticoagulant Drugs Market, By Application, 2015-2027 (USD Million)
7. North America Peptide and Anticoagulant Drugs Market, By End Users, 2015-2027 (USD Million)
8. Europe Peptide and Anticoagulant Drugs Market, By Type, 2015-2027 (USD Million)
9. Europe Peptide and Anticoagulant Drugs Market, By Application, 2015-2027 (USD Million)
10. Europe Peptide and Anticoagulant Drugs Market, By End Users, 2015-2027 (USD Million)
11. Asia Pacific Peptide and Anticoagulant Drugs Market, By Type, 2015-2027 (USD Million)
12. Asia Pacific Peptide and Anticoagulant Drugs Market, By Application, 2015-2027 (USD Million)
13. Asia Pacific Peptide and Anticoagulant Drugs Market, By End Users, 2015-2027 (USD Million)
14. Middle East & Africa Peptide and Anticoagulant Drugs Market, By Type, 2015-2027 (USD Million)
15. Middle East & Africa Peptide and Anticoagulant Drugs Market, By Application, 2015-2027 (USD Million)
16. Middle East & Africa Peptide and Anticoagulant Drugs Market, By End Users, 2015-2027 (USD Million)
17. South America Peptide and Anticoagulant Drugs Market, By Type, 2015-2027 (USD Million)
18. South America Peptide and Anticoagulant Drugs Market, By Application, 2015-2027 (USD Million)
19. South America Peptide and Anticoagulant Drugs Market, By End Users, 2015-2027 (USD Million)
20. Global Peptide and Anticoagulant Drugs Market, Company Market Share, 2020 - 2027 (%)
21. Abbott Laboratories: Source Benchmarking
22. Abbott Laboratories: Financial Performance
23. Sanofi SA: Source Benchmarking
24. Sanofi SA: Financial Performance
25. Cipla liimited: Source Benchmarking
26. Cipla liimited: Financial Performance
27. Lupin liimited: Source Benchmarking
28. Lupin liimited: Financial Performance
29. Novartis AG Limited: Source Benchmarking
30. Novartis AG Limited: Financial Performance
31. Alkem laboratories limited: Source Benchmarking
32. Alkem laboratories limited: Financial Performance
33. Sun pharmaceutical: Source Benchmarking
34. Sun pharmaceutical: Financial Performance
35. Biocon limited: Source Benchmarking
36. Biocon limited: Financial Performance
The Leading Key Players in Peptide And Anticoagulant Drugs Market
Abbott Laboratories (U.S.)
Cadila Pharmaceuticals (India)
Sanofi S.A. (France)
Eli Lilly and Company (U.S.)
Cipla Limited (India)
Biocon Limited (India)
Intas Pharmaceuticals Ltd. (India)
Lupin Limited (India)
Emcure Pharmaceuticals Ltd. (India)
Sun Pharmaceutical Industries Ltd. (India)
Novartis International AG (Switzerland)
Dr. Reddy’s Laboratories Limited (India)
Alkem Laboratories Limited (India).
